TapewireFind a company

person · Reporting owner

Schuyler Kevin

Disclosed activity across 3 companies

Tapewire entity
53054
SEC CIK
0001718094

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742DirectorApril 07, 2026April 09, 2026
Twin Vee PowerCats, Co.VEEE · Entity 8235DirectorMarch 19, 2026March 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADIAL PHARMACEUTICALS, INC.

Report date April 07, 2026 · Filed April 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,213 Reported balance After 2026-04-07 transaction · row 1
1 source row

Row 1 · 2026-04-07 · Grant · Acquired 9,185 · Balance 9,213

F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

Common StockSEC Table I · non-derivativeIndirectOwned by Mr. Schuyler's wife, Carolyn M. Schuyler4 Reported balance Holding disclosure · report date 2026-04-07 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 4

Common StockSEC Table I · non-derivativeIndirectOwned by MVA 151 Investors, LLC230 Reported balance Holding disclosure · report date 2026-04-07 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 230

F2: Mr. Schuyler has control over MVA 151 Investors, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

F2: Mr. Schuyler has control over MVA 151 Investors, LLC.

Twin Vee PowerCats, Co.

Report date March 19, 2026 · Filed March 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common stockSEC Table I · non-derivativeDirect31,252 Reported balance After 2026-03-19 transaction · row 1
1 source row

Row 1 · 2026-03-19 · Purchase · Acquired 25,000 · Balance 31,252

F1: Open market purchase of shares in accordance with Issuer's trading policies.

Filing footnotes · ownership attribution and instrument terms

F1: Open market purchase of shares in accordance with Issuer's trading policies.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forza X1, Inc.

Report date November 26, 2024 · Filed November 26, 2024

Section 16 reporting ended · disclosed 2024-11-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-11-26 transaction · row 1
1 source row

Row 1 · 2024-11-26 · Disposition to issuer · Disposed 100,000 · Balance 0

F1: Disposed of pursuant to the merger (the "Merger") of Twin Vee Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Twin Vee PowerCats Co., a Delaware corporation ("Twin Vee"), into Forza X1, Inc. ("Forza"), in exchange for 61,166 shares of Twin Vee common stock. Each share of Forza common stock was exchanged for 0.611666275 shares of Twin Vee common stock on the effective date of the Merger.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2032-09-01Direct0 Reported balance After 2024-11-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-11-26 · Disposition to issuer · Disposed 5,500 · Balance 0

F2: Consists of options to purchase shares of common stock that are fully vested and exercisable for a period of ten years from the date of grant, commencing on September 1, 2022.

F3: This option was assumed by Twin Vee in the Merger and replaced with an option to purchase 3,364 shares of Twin Vee common stock for $8.17 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the merger (the "Merger") of Twin Vee Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Twin Vee PowerCats Co., a Delaware corporation ("Twin Vee"), into Forza X1, Inc. ("Forza"), in exchange for 61,166 shares of Twin Vee common stock. Each share of Forza common stock was exchanged for 0.611666275 shares of Twin Vee common stock on the effective date of the Merger.

F2: Consists of options to purchase shares of common stock that are fully vested and exercisable for a period of ten years from the date of grant, commencing on September 1, 2022.

F3: This option was assumed by Twin Vee in the Merger and replaced with an option to purchase 3,364 shares of Twin Vee common stock for $8.17 per share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherWarrant to purchase common stock · Derivative 113,800 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 10

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by MVA 151 Investors, LLC

Disclosed balance after: 113,800

Underlying: Common Stock · 162,200 shares

Expires 2023-07-31

F3 · price: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F3 · derivative.underlying: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F6 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 PurchaseWarrant to purchase common stock · Derivative 90,000 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 9

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,461

Underlying: Common Stock · 90,000 shares

Expires 2023-07-31

F7 · shares: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

F7 · price: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherWarrant to purchase common stock · Derivative 120,000 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 8

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,461

Underlying: Common Stock · 120,000 shares

Expires 2023-07-31

F2 · price: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F2 · derivative.underlying: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 ConversionWarrant to purchase common stock · Derivative 82,461 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 7

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,461

Underlying: Common Stock · 82,461 shares

Expires 2023-07-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 ConversionConvertible Note · Derivative 82,461 Not disclosed Strike: $0.44 Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · derivative · entry 6

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 82,461 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.

F1 · derivative.exercise_date: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.

F1 · derivative.expiration_date: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherCommon Stock 113,800 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 4

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by MVA 151 Investors, LLC

Disclosed balance after: 113,800

F3 · shares: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F3 · price: The 113,800 shares of common stock and warrants to purchase 113,800 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F6 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 PurchaseCommon Stock 90,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 3

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,390

F7 · shares: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

F7 · price: On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherCommon Stock 120,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 2

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,390

F2 · shares: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F2 · price: The 120,000 shares of common stock and warrants to purchase 120,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:11 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 ConversionCommon Stock 82,461 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-18-010092 · ownership.xml · nonDerivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,390

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.

F1 · price: The 82,461 shares of common stock and a warrant to purchase 82,461 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $27,550 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherWarrant to purchase units · Derivative 192,600 Not disclosed Strike: $5.00 Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 8

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by MVA 151 Investors, LLC

Disclosed balance after: 192,600

Underlying: Units · 385,200 shares

Expires 2023-07-31

F4 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 units was received by MVA 151 Investors LLC upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 385,200 shares.

F4 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 units was received by MVA 151 Investors LLC upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 385,200 shares.

F5 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherWarrant to purchase units · Derivative 89,600 Not disclosed Strike: $5.00 Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 7

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,600

Underlying: Units · 179,200 shares

Expires 2023-07-31

F3 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect the purchase 89,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 179,200 shares.

F3 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect the purchase 89,600 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 179,200 shares.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherWarrant to purchase common stock · Derivative 192,600 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 6

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by MVA 151 Investors, LLC

Disclosed balance after: 192,600

Underlying: Common Stock · 192,200 shares

Expires 2023-07-31

F2 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F2 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F5 · ownership.nature: Mr. Schuyler has control over MVA 151 Investors, LLC.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 PurchaseWarrant to purchase common stock · Derivative 90,000 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 5

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2023-07-31

F6 · shares: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

F6 · price: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherWarrant to purchase common stock · Derivative 89,600 Not disclosed Strike: $6.25 Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · derivative · entry 4

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,600

Underlying: Common Stock · 89,600 shares

Expires 2023-07-31

F1 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F1 · derivative.underlying: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherCommon Stock 144,200 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · nonDerivative · entry 3

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by MVA 151 Investors, LLC

Disclosed balance after: 144,200

F2 · shares: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F2 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 192,600 shares of common stock and warrants to purchase 192,600 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F6 · ownership.nature: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 PurchaseCommon Stock 90,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · nonDerivative · entry 2

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,990

F6 · shares: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

F6 · price: The original warrant number and units issuable upon exercise of the warrant is being corrected to reflect On July 31, 2018, Mr. Schuyler purchased 90,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering.

Read SEC document
July 31, 2018 Filed Nov 25, 2020 21:50 UTC Amendment ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 OtherCommon Stock 89,600 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-20-039338 · ownership.xml · nonDerivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,990

F1 · shares: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

F1 · price: The original warrant number and shares issuable upon exercise of the warrant is being corrected to reflect 89,600 shares of common stock and warrants to purchase 89,600 shares of common stock that were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.